LONDON (Reuters) – New screening tests andeffective vaccines from Merck & Co and GlaxoSmithKline maketackling cervical cancer in poor countries a real possibility forthe first time, researchers said on Thursday.

Experts who presented their findings at a conference in Genevasaid the vaccines against the disease could be cost-effective butsubsidies or new prices would be needed for developing countries toafford the medicines.

“Efforts are needed now to adapt the current price of thevaccines so they meet what individual countries can afford,”Francesco Xavier Bosch of the Catalan Institute of Oncology inBarcelona told the World Cancer Congress.

social poster